The PPRHs tested in combinations targeting both MYC and KRAS were G4-C or I1-T for MYC and PPRH2 or PR for KRAS, in both PC-3 and the previously examined AsPc-1 pancreatic cancer cell lines at a dose of 25 nM per PPRH. Here, KRAS is linked to familial pancreatic carcinoma.